Next-generation cancer immunotherapies are designed to broaden the therapeutic repertoire by targeting alternative immune inhibitory checkpoint receptors such as lymphocyte-activation gene-3 (LAG-3) [8] and T cell immunoglobulin and mucin-domain containing-3 (TIM-3) [9] to reinvigorate T-cell responses. Here, LAG3 is linked to cancer.